EFFICACY AND SAFETY EVALUATION OF RECOMBINANT HUMAN GROWTH HORMONE (R-HGH), SAIZEN®, ON A POPULATION OF CHILDREN WITH HYPOCHONDROPLASIA, TREATED AT LEAST 3 YEARS OR UNTIL NEAR FINAL HEIGHT, WHEN APPLICABLE, IN COMPARISON WITH A HISTORIC COHORT OF NON-TREATED CHILDREN: